Latest news with #OptimizeRx
Business Insider
4 days ago
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX) and Relay Therapeutics (RLAY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on OptimizeRx (OPRX – Research Report) and Relay Therapeutics (RLAY – Research Report). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. OptimizeRx (OPRX) In a report released yesterday, Richard Baldry from Roth MKM reiterated a Buy rating on OptimizeRx, with a price target of $27.00. The company's shares closed last Thursday at $12.84, close to its 52-week high of $14.13. According to Baldry is a 5-star analyst with an average return of 17.4% and a 58.6% success rate. Baldry covers the Technology sector, focusing on stocks such as Zeta Global Holdings Corp, FiscalNote Holdings, and Research Solutions. Currently, the analyst consensus on OptimizeRx is a Strong Buy with an average price target of $17.80, representing a 39.7% upside. In a report issued on August 4, Lake Street also maintained a Buy rating on the stock with a $19.00 price target. Relay Therapeutics (RLAY) Oppenheimer analyst Matthew Biegler reiterated a Hold rating on Relay Therapeutics yesterday. The company's shares closed last Thursday at $3.49, close to its 52-week low of $2.69. According to Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.8% and a 31.9% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals. Relay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.20, which is a 240.8% upside from current levels. In a report issued on August 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $3.50 price target.
Business Insider
4 days ago
- Business
- Business Insider
OptimizeRx price target raised to $27 from $22 at Roth Capital
Roth Capital raised the firm's price target on OptimizeRx (OPRX) to $27 from $22 and keeps a Buy rating on the shares after its 'very strong' Q2 results. The firm cites the company's revenues and adjusted EBITDA both sharply above forecasts. OptimizeRx is well positioned for accelerated growth in 2025 and beyond, an outlook that is still at odds with its still-muted 2025 revenue growth guidance of 13%-17%, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Globe and Mail
17-07-2025
- Business
- Globe and Mail
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the 'Company') (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Please call the conference telephone number or log on to the web access link five minutes prior to the start time. A replay of the call will remain available for 12 months via the Investors section of the OptimizeRx website at About OptimizeRx OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes. Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world's leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
Yahoo
04-07-2025
- Business
- Yahoo
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
OptimizeRx OPRX kicked off 2025 with strong momentum, delivering 11% year-over-year revenue growth to $21.9 million and turning in $1.5 million in adjusted EBITDA, its strongest first-quarter performance to date. The digital health company's cost discipline and strategic client engagement efforts translated into a narrower net loss and stronger operating cash flow of $3.9 million, supporting a cash balance of $16.6 million. The company raised full-year revenue guidance to $101-$106 million and expects adjusted EBITDA between $13-$15 million, citing a strong pipeline. The company's existing contracts are likely to generate more than 80% of the revenue guidance. A notable strategic shift is the move toward a subscription-based revenue model, with early adoption already exceeding 5% of projected revenues. This shift, coupled with a broad and scalable tech platform, is designed to smooth revenue flows, enhance margins and deepen client stickiness. However, gross margins came in slightly lower at 60.9% versus 62% last year, reflecting a higher mix of lower-margin DTC managed services. While management aims to lift margins over time, the current mix suggests some near-term pressure depending on solution uptake. Critically, pharma clients are increasingly focused on efficiency and ROI in their marketing budgets amid regulatory shifts and evolving channel strategies. OptimizeRx's omnichannel platform — leveraging point-of-care integration and real-world patient targeting — appears well aligned with these priorities. Early results show a script lift of 25% and a 10:1 ROI, reinforcing its value proposition. OptimizeRx is navigating macro uncertainty with agility, benefiting from a growing base of committed revenues, cost efficiencies and a pivot to subscriptions. Continued execution in monetizing data and deepening customer relationships will be key to sustaining profit growth as pharma spending recalibrates in an increasingly digital landscape. Veeva Systems VEEV reported strong first-quarter fiscal 2026 results with $759 million in revenues, up 16.7% year over year, driven by robust adoption of Vault CRM and Crossix. Management remains optimistic despite macro uncertainty, emphasizing resilient subscription revenues and a growing product pipeline. Crossix, which offers short-cycle ROI on pharma marketing, is seeing over 30% year-over-year growth and is viewed as relatively insulated from budget pressure. The company is also advancing Veeva AI to deepen customer value and aims to increase commercial productivity, positioning itself as a critical partner as pharma clients prioritize efficiency and measurable outcomes. Health Catalyst HCAT delivered $79.4 million in first-quarter of 2025 revenue, up 6.3% year-over-year, with its tech platform Ignite driving 10% growth. Amid shifting pharma and healthcare funding, HCAT's modular, lower-cost Ignite platform enables faster ROI and shorter sales cycles, making it attractive in constrained budget environments. The company sees strong client uptake, particularly from existing app users, and expects 40 net new Ignite clients in 2025. While some booking delays occurred due to Medicaid and research funding uncertainty, HCAT believes the long-term value and pricing flexibility of Ignite will sustain growth. Full-year guidance was maintained, reflecting confidence in pipeline conversion. Shares of OptimizeRx have surged 176.4% year to date compared with the industry's growth of 15%. Image Source: Zacks Investment Research OPRX's forward 12-month P/S of 2.25X is lower than the industry's average of 8.67X, and also lower than its five-year median of 3.63X. However, it carries a Value Score of F. Image Source: Zacks Investment Research The Zacks Consensus Estimate for OPRX's 2025 earnings per share suggests a 63.6% improvement from 2024. Image Source: Zacks Investment Research OptimizeRx stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report OptimizeRx Corp. (OPRX) : Free Stock Analysis Report Veeva Systems Inc. (VEEV) : Free Stock Analysis Report Health Catalyst, Inc. (HCAT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
04-07-2025
- Business
- Yahoo
Investors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three years
It is doubtless a positive to see that the OptimizeRx Corporation (NASDAQ:OPRX) share price has gained some 73% in the last three months. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 55% in the last three years. Some might say the recent bounce is to be expected after such a bad drop. While many would remain nervous, there could be further gains if the business can put its best foot forward. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Because OptimizeRx made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over three years, OptimizeRx grew revenue at 16% per year. That's a fairly respectable growth rate. So some shareholders would be frustrated with the compound loss of 16% per year. The market must have had really high expectations to be disappointed with this progress. So this is one stock that might be worth investigating further, or even adding to your watchlist. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts It's good to see that OptimizeRx has rewarded shareholders with a total shareholder return of 34% in the last twelve months. Notably the five-year annualised TSR loss of 1.3% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - OptimizeRx has 1 warning sign we think you should be aware of. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
